Collaborator: Policy Lab U.S

This is an open-label, ten-week, clinical trial of a proprietary high CBD/low THC sublingual solution (20mg/ml CBD and 0.58mg/ml THC) for the treatment of clinically significant anxiety and agitation in mild to moderate Alzheimer’s Disease.


Recruitment Status: Recruiting
Study Details:
Sponsor: Mclean Hospital
Collaborator: Spier Family Foundation
Information provided by (Responsible Party): Brent Forester, Mclean Hospital
Condition or Disease: Alzheimer Disease, Anxiety, Agitation, Psychomotor
Intervention/Treatment: Drug: High CBD/ Low THC sublingual solution
Phase: Phase 2
Study Type: Interventional (Clinical Trial)
Estimated Enrolment: 12 participants
Intervention Model: This is an open-label trial; all participants will receive the active drug.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-Label Trial of a Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Alzheimer’s Dementia
Estimated Study Start Date: March 1, 2020
Estimated Primary Completion Date: November 1, 2021
Estimated Study Completion Date: November 1, 2021

CBD Products

See all posts by CBD Products

Participate in CBD Research

CBD World News is part of an active community, working to enhance our understanding of the benefits of CBD. You can become an active part of that community too, by taking part in our collaborative research. We are interested in finding out who is using CBD, how it is used, and what it is used for?

Taking part in this research will help bring the good word of CBD to life and help people all over the world discover the benefits of cannabinoids.